Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors
Open Access
- 18 August 2016
- journal article
- Published by Ferrata Storti Foundation (Haematologica)
- Vol. 101 (12), 1499-1507
- https://doi.org/10.3324/haematol.2016.144808
Abstract
Iron overload due to hemochromatosis or chronic blood transfusions has been associated with the development of osteoporosis. However, the impact of changes in iron homeostasis on osteoblast functions and the underlying mechanisms are poorly defined. Since Wnt signaling is a critical regulator of bone remodeling, we aimed to analyze the effects of iron overload and iron deficiency on osteoblast function, and further define the role of Wnt signaling in these processes. Therefore, bone marrow stromal cells were isolated from wild-type mice and differentiated towards osteoblasts. Exposure of the cells to iron dose-dependently attenuated osteoblast differentiation in terms of mineralization and osteogenic gene expression, whereas iron chelation with deferoxamine promoted osteogenic differentiation in a time- and dose-dependent manner up to 3-fold. Similar results were obtained for human bone marrow stromal cells. To elucidate whether the pro-osteogenic effect of deferoxamine is mediated via Wnt signaling, we performed a Wnt profiler array of deferoxamine-treated osteoblasts. Wnt5a was amongst the most highly induced genes. Further analysis revealed a time- and dose-dependent induction of Wnt5a being up-regulated 2-fold after 48 h at 50 μM deferoxamine. Pathway analysis using specific inhibitors revealed that deferoxamine utilized the phosphatidylinositol-3-kinase and nuclear factor of activated T cell pathways to induce Wnt5a expression. Finally, we confirmed the requirement of Wnt5a in the deferoxamine-mediated osteoblast-promoting effects by analyzing the matrix mineralization of Wnt5a-deficient cells. The promoting effect of deferoxamine on matrix mineralization in wild-type cells was completely abolished in Wnt5a−/− cells. Thus, these data demonstrate that Wnt5a is critical for the pro-osteogenic effects of iron chelation using deferoxamine.Keywords
This publication has 53 references indexed in Scilit:
- Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitectureBone, 2014
- The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stressFree Radical Biology & Medicine, 2013
- Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration After Tissue InjuryScience, 2012
- Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cellsBone, 2010
- Deferoxamine mesylate is toxic for retinal pigment epithelium cellsin vitro, and its toxicity is mediated by p38Cutaneous and Ocular Toxicology, 2010
- Promotion of osteogenesis through β-catenin signaling by desferrioxamineBiochemical and Biophysical Research Communications, 2008
- Iron chelation acutely stimulates fetal human intestinal cell production of IL-6 and VEGF while decreasing HGF: the roles of p38, ERK, and JNK MAPK signalingAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Dietary determinants of post-menopausal bone loss at the lumbar spine: a possible beneficial effect of ironOsteoporosis International, 2006
- LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye DevelopmentCell, 2001
- Metal Chelation as a Potential Therapy for Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2000